Who makes PRGN-2012 - Phase II; Dose Level 2?

PRGN-2012 - Phase II; Dose Level 2 is developed by Precigen, Inc.

What development phase is PRGN-2012 - Phase II; Dose Level 2 in?

PRGN-2012 - Phase II; Dose Level 2 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

PRGN-2012 - Phase II; Dose Level 2

Precigen, Inc · Phase 1 active Small molecule

At a glance

Generic name	PRGN-2012 - Phase II; Dose Level 2
Sponsor	Precigen, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PRGN-2012 - Phase II; Dose Level 2 CI brief — competitive landscape report
PRGN-2012 - Phase II; Dose Level 2 updates RSS · CI watch RSS
Precigen, Inc portfolio CI